Research Index
Retatrutide Research Index
PSI surfaces 50 peer-reviewed studies on Retatrutide, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
Bellido V, le Roux CW, Ekinci EI et al.
Lancet·2026·Human·PubMed →
Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis.
Branine N
Cureus·2026·Human·PubMed →
Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.
Wu X, Yang Y, Cui X et al.
Front Pharmacol·2026·Human·PubMed →
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Bajaj HS, Welch M, Shah P et al.
Lancet·2026·Human·Glycemic Control·PubMed →
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
Pearson MJ, Willency JA, Lin Y et al.
J Clin Endocrinol Metab·2026·Human·PubMed →
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.
Heerspink HJL, van Raalte DH, Bjornstad P et al.
Nephrol Dial Transplant·2026·Human·Glycemic Control, Weight Loss·PubMed →
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
Jastreboff AM, Kaplan LM, Davies MJ et al.
N Engl J Med·2026·Animal·PubMed →
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Amjad MM, Khan MM, Sarwar F et al.
Diabetes Obes Metab·2026·Animal·PubMed →
Future GLP-1 receptor co-agonists and their cardiac effects.
Neumann J, Kirchefer U, Hofmann B et al.
Naunyn Schmiedebergs Arch Pharmacol·2026·Animal·PubMed →
Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.
Yovera-Aldana M, Manrique-Hurtado H, Umpierrez GE
JCEM Case Rep·2026·Animal·PubMed →
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR et al.
Rapid Commun Mass Spectrom·2026·Animal·PubMed →
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
Petersen J, Merrild C, Holm SK et al.
Nat Metab·2026·Animal·PubMed →
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
Ravic M, Srejovic IM, Milosavljevic I et al.
Can J Physiol Pharmacol·2026·Animal·PubMed →
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
Chen D, Ma B, Sun H et al.
BMJ Med·2026·Animal·PubMed →
Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.
Kim Y, Lee EY, Korean Diabetic Kidney Disease Study Group
Kidney Res Clin Pract·2026·Animal·PubMed →
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception.
Koca N, Uyar S, Şahintürk Y et al.
Cardiovasc Diabetol·2026·Animal·Glycemic Control·PubMed →
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
Ding M, Li X, Wei Y et al.
iScience·2026·Animal·PubMed →
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.
Ruotolo G, Harris C, Lin Y et al.
Diabetes Obes Metab·2026·Animal·PubMed →
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Tong LH, Leung KK, Hung CT
J Chromatogr A·2026·Animal·PubMed →
Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it.
Brown C
BMJ·2026·Animal·PubMed →
Integrating glucagon-like peptide-1 receptor agonists into dermatology practice: Safety and monitoring strategies.
Narla S, Narla RR
Clin Dermatol·2026·Animal·PubMed →
Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia.
Piatkowski T, Craven A, Cornell S et al.
Drug Alcohol Rev·2026·Animal·PubMed →
Retatrutide effects on diabetic rats' cognition.
Ferreira J
Lab Anim (NY)·2026·Animal·PubMed →
Retatrutide and the urinary tract infection signal: Is the answer hidden in timing?
Koufakis T, Argyrakopoulou G, Kokkinos A et al.
Eur J Intern Med·2026·Animal·PubMed →
Medical Treatments for Obesity: What Does the Future Have in Store?
Bassatne A, Rizo I
J Clin Endocrinol Metab·2026·Animal·PubMed →
Retatrutide fact check: Has a man died after taking the unapproved weight loss jab?
Mahase E
BMJ·2026·Animal·PubMed →
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Keskin U, Altın E, Kara MK et al.
Behav Brain Res·2026·Animal·Cognitive Enhancement·PubMed →
Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.
Lang K
BMJ·2026·Animal·PubMed →
A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide.
Mao CY, Pang ZJ, Qiao GY et al.
Org Lett·2026·Animal·PubMed →
Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.
Chalhoub X, Yang Ng Z
Aesthet Surg J·2026·Animal·PubMed →
A retrospective audit of weight loss and health outcomes following bariatric surgery at a tertiary public hospital.
Lee JP, Bahamdan A, Franklin J et al.
Obes Res Clin Pract·2026·Animal·Weight Loss, Glycemic Control·PubMed →
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.
Pillai AA, Godin SL, Frishman WH et al.
Cardiol Rev·2026·Animal·PubMed →
GIPR:GCGR co-agonism restores normal weight in obese rodents.
Perez-Tilve D, Zhang F, Zhang Y et al.
Mol Metab·2026·Animal·Weight Loss, Glycemic Control·PubMed →
Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair.
Li Q, Cheng W, Zhang J et al.
Diabetol Metab Syndr·2026·Animal·PubMed →
Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
Briand F, Le Cudennec C, Grasset E et al.
Obesity (Silver Spring)·2026·Animal·Weight Loss, Glycemic Control, Liver Protection, Liver Fat (MASLD)·PubMed →
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
Hitaka K, Sugawara T, Matsumoto M et al.
Int J Obes (Lond)·2026·Animal·Weight Loss·PubMed →
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
Chan ZH, Omar AS, Gill K et al.
Cardiol Rev·2026·Animal·PubMed →
Development of the Weight and Emotions Scale (WES).
Kanu C, Kimel M, Goetz I et al.
Obes Sci Pract·2026·Animal·PubMed →
[Nephrology : what's new in 2025].
Nanchen G, Pruijm M, Lamine F et al.
Rev Med Suisse·2026·Animal·Glycemic Control·PubMed →
Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
Goetz IA, Kanu C, Hoover A et al.
Obes Pillars·2025·Human·PubMed →
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
Kanu C, Boye KS, Poon JL et al.
Diabetes Obes Metab·2025·Human·Glycemic Control, Appetite Regulation, Weight Loss·PubMed →
Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight.
Kanu C, Wu Q, Poon JL et al.
Diabetes Obes Metab·2025·Human·PubMed →
Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.
Wen Y, Lemen D, Lin Y et al.
Diabetes Obes Metab·2025·Human·Glycemic Control·PubMed →
The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.
Heerspink HJL, Lu Z, Du Y et al.
Kidney Int Rep·2025·Human·PubMed →
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Coskun T, Wu Q, Schloot NC et al.
Lancet Diabetes Endocrinol·2025·Human·Glycemic Control·PubMed →
Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.
Guo H, Yang J, Huang J et al.
Obes Pillars·2025·Human·PubMed →
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
Xie Z, Zheng G, Liang Z et al.
Metabolism·2024·Human·Weight Loss·PubMed →
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Sanyal AJ, Kaplan LM, Frias JP et al.
Nat Med·2024·Human·Liver Fat (MASLD), Liver Protection, Weight Loss·PubMed →
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, Frias J, Jastreboff AM et al.
Lancet·2023·Human·PubMed →
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP et al.
N Engl J Med·2023·Human·PubMed →